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ABSTRACT: The synthesis of optically and diastereomerically pure P-stereogenic 
phosphine-imidazole ligands is reported. The new ligands contain either a 
benzoimidazole or a 4-phenylimidazole as a N-donor fragment. The ligands have been 
coordinated to iridium and the structure of the corresponding cationic COD complexes 
has been determined by X-ray analysis. The combination of the chiral phosphorus atom 
and the imidazole substituents generate a strong chiral environment around the metal 
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center. Preliminary hydrogenation reactions with a model cyclic -enamide are also 
reported.  
INTRODUCTION 
The use of P-stereogenic ligands (P*) is as old as organometallic asymmetric catalysis.1 
Although at some point this family of ligands fell from favor, in the last decades a number 
of research groups have developed new type of P*-ligands which may be recognized 
among the most effective ligands in the chemist toolbox.2-4 Since 2010, our group has 
developed different P-stereogenic synthons that can be conveniently used to assemble P-
P, P-O and P-N ligands.5-7 Among these synthons, we have recently reported the synthesis 
of optically pure tert-butylmethylphosphinous acid borane 1, which we used in the 
synthesis of P-stereogenic phosphino-oxazoline MaxPHOX family of ligands. 
MaxPHOX ligands have provided excellent results in the Ir-catalyzed asymmetric 
isomerization and hydrogenation reactions.8-12 P,N-Iridium complexes with imidazole as 
heterocyclic N-donor group have been reported in the literature, however, to our 
knowledge none of these contain a P-stereogenic phosphine.13,14 In this work we report 
on the synthesis, coordination and X-ray structures of phosphine-imidazole ligands 
derived from phosphinous acid 1 and valine. Preliminary asymmetric hydrogenation 
reactions of a model cyclic -enamide are also reported.  
 
 





RESULTS AND DISCUSSION 
Ligand Synthesis. Phosphino imidazole ligands have been synthetized according to 
the retrosynthetic analysis shown in Scheme 1. Condensation of valine with ortho-
phenylenendiamine and 2-bromoacetophenone should provide the corresponding chiral 
protected benzo- and 4-phenylimidazole amines. N-Alkylation and Boc deprotection 
would provide the corresponding primary amines. These will be coupled with either 
enantiomer of the optically pure tert-butylmethylphosphinous acid borane in a SN2 
reaction at the stereogenic P-center (SN2@P) to afford the desired ligands.  
 
 
Scheme 1: Retrosynthetic plan for the synthesis of phosphino imidazole ligands. 
The synthesis of free (R)-2-methyl-1-(1-methylbenzoimidazol-2-yl)propan-1-amine 4 
was conducted as shown in Scheme 2. Condensation of N-Boc valine with ortho-
phenylenendiamine was carried out through a two-step procedure as described in the 
literature.15 Isobutyl chlorocarbonate-mediated amide coupling and cyclization with 
AcOH at 65 ºC provided the desired N-Boc protected benzoimidazole 2 in 54% yield. 
Next, N-methylation of the benzoimidazole heterocycle was carried selectively with MeI 
and NaOH pellets in acetonitrile. This cleanly afforded 3 in 90% yield. Finally, Boc 
deprotection was performed in MeOH/HCl(aq) which afforded the desired 





Scheme 2: Synthesis of benzoimidazole amine 4.  
 
 
 Phenylimidazole amine was synthesized as indicated in Scheme 3. Compound 5 was 
synthesized as described in the literature in a two-step process.16 Reaction of the 
phenacylbromide with N-Boc valine in Et3N/EtOAc afforded the phenacyl ester which 
was cyclized with NH4OAc in refluxing toluene to yield N-Boc protected 
phenylimidazole 5 in 63% overall yield. N-methylation of 5 with MeI/NaOH at 0 ºC 
provided a 1:10 mixture of regioisomers 6a/6b as determined by 1H NMR. After 
separation of the isomers by flash chromatography, NOESY experiments showed a cross-
peak between the imidazole hydrogen and the N-CH3 group in the major isomer 6a, while 
for 6b a cross peak was observed for Ph-Hortho and the N-CH3 group (Figure 2). This 
means that the alkylation takes place preferably at the less hindered nitrogen on the azole 
ring. Finally, from pure 6a, MeOH/HClaq deprotection of the Boc group afforded the 
desired phenylimidazole amine 7 in 68 % yield.  
 






Figure 2: NOESY experiments on 6a and 6b isomers. nOe % was calculated with respect 
the CH(NHBoc)/CH3(iPr) nOe signal.  
With the pure imidazole amines 4 and 7 in hand we proceeded to couple them with the 
chiral phosphorus synthon. As we have recently reported,17 pure tert-
butylmethylphosphinous acid borane 1 has limited stability, while the corresponding 
dialkylammonium salts are shelf-stable crystalline solids that can be stored indefinitely. 
Moreover, they can be directly used in coupling reactions with primary amines. Thus, 
activation at -20 ºC of either enantiomer of 1·DA (diisopropylammonium salt) with the 
methansulfonic anhydride provides the corresponding mixed anhydride which undergoes 
reaction with amines with inversion of configuration (Scheme 4). Reaction with 
benzoimidazole amine 4 provided diastereomers (SP)-8 and (RP)-8, which only differ from 
the configuration at the phosphorus center, with 96 and 76% yield respectively. In the 
same manner, reaction with phenyl imidazole 7 provided diastereomer (SP)-9 (99%) and 
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(RP)-9 (57%). In all four cases the compounds were isolated as diastereomerically pure 
substances as judged by 1H NMR analysis.  
 
Scheme 4: Amine coupling with the P-stereogenic phosphinous acid salt.  
 
 
Iridium complexes: Synthesis, structure and catalysis. Ligands 8 and 9 were 
coordinated to iridium in a one pot 3-step procedure, as shown in Scheme 5. Borane 
deprotection was carried out in neat pyrrolidine (90 ºC) under nitrogen atmosphere, the 
pyrrolidine was removed under vacuum and [Ir(COD)Cl]2 in CH2Cl2 was added. Finally, 
addition of NaBArF produced the counteranion exchange. The cationic complexes were 
easily purified by flash chromatography in hexanes/DCM. Higher yields were observed 
for complexes Ir-(SP)-8 and Ir-(SP)-9 with trans configuration of tBu/iPr groups, which 
may respond to a major chelate stability.  
 




To figure out how these ligands accommodate around the iridium metal center we 
sought to determine the solid-state structure of such complexes. Upon layering hexanes 
on top of a DCM solution of the pure samples, we could obtain single crystals suitable 
for X-ray analysis for complexes Ir-(SP)-8, Ir-(SP)-9 and Ir-(RP)-9.
18 Compound Ir-(RP)-
8 precipitated as an oil. The corresponding Ortep drawings are depicted in Figure 3. All 
three structures share a boat conformation of the 6-membered ligand-metal chelate. The 
isopropyl group is in axial position for all 3 structures, thus avoiding steric strain with the 
N-methyl group on the imidazole heterocycle. Because of this, the -CH- proton of the iPr 
group is in close proximity to the Ir centre (2.64-2.80 Å). For Ir-(SP)-8 and Ir-(SP)-9 with 
SP,S configuration,
19 the tBu group is axial, in what it seems its preferred disposition, 
away from the cyclooctadiene ligand. In Ir-(RP)-9 the tBu group is in equatorial position 
and to some extent clashes with the cyclooctadiene ligand producing a noticeable 
distortion. X-ray structure of Ir-(SP)-9 and Ir-(RP)-9 confirmed that N-methylation had 
taken place at the less hindered nitrogen atom of the imidazole. Finally, we should also 
highlight that both benzoimidazole and phenylimidazole P*,N ligands produce an 
effective chiral environment around the metal centre. For the phenylimidazole 
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derivatives, the phenyl group lies right above the metal producing slightly higher steric 
encumbrance.  
 
Figure 3: X-ray structures for complexes Ir-(SP)-8, Ir-(SP)-9 and Ir-(RP)-9. Ortep 
drawing displays ellipsoids at 50% probability. BArF counter ions have been omitted for 




Finally, we tested the complexes Ir-8 and Ir-9 in the asymmetric hydrogenation of N-
acetyl-3,4-dihydronaphthalen-2-amine. Cyclic -enamides are challenging substrates to 
reduce and the resulting chiral amines have biological and therapeutical interest since 
they are precursors of drugs like rotigotine, a treatment for Parkinson’s disease.20 
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Hydrogenation of such substrates has been reported recently by our group with excellent 
conversions and ee using Ir-MaxPHOX family of catalysts.9 
In the present case the reaction conditions we employed were: 1 mol % catalyst loading, 
3 bars of H2 overnight at room temperature in DCM. With this set of conditions, the 
conversions were low for all four catalysts (Table 1, entries 1-4). To attain higher 
conversions, we increased the pressure to 50 bars of hydrogen (Table 1, entries 4-8). 
Indeed, higher conversions and selectivities were observed, the best result being with Ir-
(RP)-8 which reported almost complete conversion and 89% enantiomeric excess (Table 
1, entry 6). The activity of the present catalytic system is somewhat reduced with respect 
to the MaxPHOX family of catalysts which contain an oxazoline as a N-donor group. 
Such a decrease on activity could be caused by structural/steric differences between the 
two N-donor moieties. Also, electronic factors could be involved. N-Alkyl imidazoles are 
more electron rich that oxazolines. It is know that phoshino imidazole ligands are among 
the most electron-rich P,N systems.14  
 
Table 1: Asymmetric hydrogenation of N-acetyl-3,4-dihydronaphthalen-2-amine.  
 
Entry Catalyst H2 Conv. (%)
a ee (%)b 
1 Ir-(SP)-8 3 bar 5 n.d.c 
2 Ir-(RP)-8 3 bar 12 n.d.c 
3 Ir-(SP)-9 3 bar 35 57 
4 Ir-(RP)-9 3 bar 10 n.d.c 
5 Ir-(SP)-8 50 bar 35 86 
6 Ir-(RP)-8 50 bar 98 89 
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7 Ir-(SP)-9 50 bar 59 59 
8 Ir-(RP)-9 50 bar 72 72 
a) Conversion was determined by 1H NMR analysis of the reaction 
crude. b) Enantiomeric excess determined by chiral HPLC. c) n.d. = 
not determined.  
 
CONCLUSIONS 
A synthetic route to prepare optically and diastereomerically pure P-stereogenic 
phosphino imidazole ligands has been optimized. Up to 4 ligands have been prepared in 
good yields. The ligands contain either a benzoimidazole or a 4-phenylimidazole N-donor 
fragment. These ligands have been coordinated to iridium to afford the corresponding 
cationic COD complexes. The solid-state structures of Ir-8S, Ir-9S and Ir-9R have been 
determined by X-ray analysis. The combination of the chiral phosphorus atom and the 
imidazole substituents generate a strong chiral environment around the metal center; 
however, the catalytic activity of the imidazole ligands is low in comparison with the 
oxazoline analogs.  
 
EXPERIMENTAL SECTION 
General methods. All reactions were carried out in dried solvents under nitrogen 
atmosphere. Et2O and CH2Cl2 were dried in a purification system. Other commercially 
available reagents and solvents were used with no further purification. Thin layer 
chromatography was carried out using TLC-aluminum sheets with silica gel. Flash 
chromatography was performed by using an automated chromatographic system with 
hexane/ethyl acetate or hexane/dichloromethane gradients as eluents, unless otherwise 
stated. NMR spectra were recorded at 23°C on a 400 MHz, 500 MHz or 600 MHz 
apparatus. 1H NMR and 13C NMR spectra were referenced either to relative internal TMS 
or to residual solvent peaks. 31P NMR spectra were referenced to phosphoric acid. Optical 
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rotations were measured at room temperature (25°C) and concentration is expressed in 
g/100 mL. Melting points were determined using a Büchi apparatus and were not 
corrected. IR spectra were recorded in a FT-IR apparatus. HRMS were recorded in a 
LTQ-FT spectrometer using the Nanoelectrospray technique. Boc protected amines 2 and 
5 were prepared according to described procedures.15,16 
 
(R)-N-Boc-2-methyl-1-(1-methyl-1H-benzo[d]imidazol-2-yl)propan-1-amine, (3). 15 
N-Boc protected imidazole amine 2 (3.50 g, 12 mmol), NaOH (pellets) (1,10 g, 28 mmol) 
in acetonitrile (30 mL) was stirred at room temperature. Iodomethane (0.75 ml, 12 mmol) 
was added and the solution was stirred overnight at room temperature. Upon completion 
of the reaction as monitored by TLC, the solvent was removed under reduced pressure. 
The crude was partitioned with H2O/CH2Cl2 and the aqueous phase was extracted three 
times with CH2Cl2. The organic phase was washed with water and dried over anhydrous 
MgSO4 and the solvent was removed under vacuum to afford 3 as white solid (2.95 g, 
80%).  
1H NMR (400 MHz, CDCl3) δ 7.76 – 7.71 (m, 1H), 7.38 – 7.26 (m, 4H), 7.25 (d, J = 2 
Hz, 0H), 5.43 (d, J = 10 Hz, 1H), 4.80 (dd, J = 10, 8 Hz, 1H), 3.83 (s, 3H), 2.30 (dq, J = 
14, 7 Hz, 1H), 1.41 (s, 9H), 1.06 (d, J = 7 Hz, 3H), 0.92 (d, J = 7 Hz, 3H) ppm. 
 
(R)-2-methyl-1-(1-methyl-1H-benzo[d]imidazol-2-yl)propan-1-amine, (4).15 
Methyl imidazole amine 3 (1.95 g, 6.4 mmol), MeOH (32 ml) and HCl 3M (32 ml) were 
stirred overnight at room temperature. Then, the MeOH was removed under reduced 
pressure and the aqueous layer was extracted twice with EtOAc. The combined organic 
layers were dried over anhydrous MgSO4 and the solvent evaporated under vacuum. This 
afforded 4 as a white solid (1.15 g, 88%). 
IR (KBr) ʋmax: 3366, 3053, 2959, 2869, 1614, 1467 cm
-1. 1H NMR (400 MHz, CDCl3) δ 
7.77 – 7.71 (m, 1H), 7.35 – 7.31 (m, 1H), 7.29 – 7.23 (m, 2H), 3.91 (d, J = 7 Hz, 1H), 
3.79 (s, 3H), 2.17 (h, J = 7 Hz, 1H), 1.05 (d, J = 7 Hz, 3H), 0.95 (d, J = 7 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3) δ 157.6 (C), 142.2 (C), 135.77 (C), 122.2 (CH), 121.9 (CH), 
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119.4 (CH), 109.1 (CH), 54.8 (CH), 34.3 (CH), 30.0 (CH3), 20.0 (CH3), 18.1 (CH3) ppm. 
HRMS (ESI): calc for [M+H]+: 204.1495, found 204.1493.  
 
(R)-N-Boc-2-methyl-1-(1-methyl-4-phenyl-1H-imidazol-2-yl)propan-1-amine, (6a).  
N-Boc protected imidazole amine 516 (2.50 g, 8 mmol), NaOH (pellets) (0.63 g, 16 mmol) 
in acetonitrile (50 mL) was stirred at 0 ºC. Iodomethane (0.49 ml, 12 mmol) was added 
and the solution was let to warm stirring overnight to room temperature. Upon completion 
of the reaction as monitored by TLC, the solvent was removed under reduced pressure. 
The crude was partitioned with H2O/CH2Cl2 and the aqueous phase was extracted three 
times with CH2Cl2. The CH2Cl2 phase was washed with water and dried over anhydrous 
MgSO4, and the solvent was removed under vacuum to afford a 6a/6b as an oil. Flash 
column chromatography (SiO2, hexane/EtOAc) allowed separation of both isomers to 
yield 1.93 g (74%) of 6a and 0.19 g (7%) of 6b. 
6a: [α]D: –91.8 (c 1.00, CHCl3). IR (KBr) ʋmax: 3302, 2972, 1705, 1496, 1170 cm
-1. 1H 
NMR (400 MHz, CDCl3) δ 7.76 – 7.68 (m, 2H), 7.34 (dd, J = 8, 7 Hz, 2H), 7.27 – 7.16 
(m, 1H), 7.01 (d, J = 2 Hz, 1H), 5.52 (d, J = 9 Hz, 1H), 4.56 (dd, J = 9 and 8 Hz, 1H), 
3.64 (s, 3H), 2.25 (dp, J = 8, 7 Hz, 1H), 1.43 (s, 9H), 1.04 (d, J = 7 Hz, 3H), 0.90 (d, J = 
7 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.71 (C), 155.4 (C), 136.3 (C), 135.1 
(C), 129.0 (CH), 128.0 (CH), 126.8 (CH), 123.0 (CH), 119.6 (CH), 110.4 (CH), 79.8 (C), 
52.5 (CH), 47.3 (CH), 33.1 (CH3), 28.4 (3xCH3), 19.8 (CH3), 18.5 (CH3) ppm. HRMS 
(ESI): Calc for [M+H]+: 330.2176, found 330.2180.  
6b: [α]D: –66.0 (c 1.02, CHCl3). IR (KBr) ʋmax: 3295, 2973, 2931, 1682, 1508, 1169 cm
-
1. 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 (m, 2H), 7.40 – 7.34 (m, 3H), 7.26 (s, 1H), 
7.03 (s, 1H), 5.38 (d, J = 10 Hz, 1H), 4.64 (dd, J = 10 and 8 Hz, 1H), 3.62 (s, 3H), 2.33 – 
2.19 (m, 1H), 1.44 (d, J = 4 Hz, 9H), 1.05 (d, J = 7 Hz, 3H), 0.93 (d, J = 7 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3) δ 155.9 (C), 133.6 (C), 130.2 (CH), 129.0 (CH), 128.8 (CH), 
128.1 (CH), 126.3 (CH), 79.6 (C), 52.6 (CH), 33.6 (CH), 31.5 (CH3), 28.5 (3xCH3), 19.7 
(CH3), 18.6 (CH3) ppm. HRMS (ESI): Calc for [M+H]





Methyl imidazole amine 6a (1.54 g, 4.7 mmol), MeOH (25 ml) and HCl 3M (25 ml) were 
stirred overnight at room temperature. Then, MeOH was removed under reduced pressure 
and the aqueous layer was extracted twice with EtOAc. The combined organic layers 
were dried over anhydrous MgSO4 and the solvent evaporated under reduced pressure. 
The resulting crude was disaggregated with Et2O and filtered to afford 7 as a white solid 
(0.73 g, 68%).  
 [α]D: –27.0 (c 1.04, CHCl3). IR (KBr) ʋmax: 3418, 3133, 2965, 2876, 1607 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ 7.77 – 7.69 (m, 2H), 7.39 – 7.30 (m, 2H), 7.20 (ddt, J = 8, 7 and 1 
Hz, 1H), 7.04 (s, 1H), 3.70 (d, J = 7 Hz, 1H), 3.66 (s, 3H), 2.16 – 2.01 (m, 1H), 1.05 (d, 
J = 7 Hz, 3H), 0.89 (d, J = 7 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 151.3 (C), 
140.1 (C), 134.6 (C), 128.6 (CH), 126.6 (CH), 125.0 (CH), 116.5 (CH), 54.7 (CH), 34.7 
(CH), 33.0 (CH3), 20.0 (CH3), 18.7 (CH3) ppm. HRMS (ESI): calc for [M+H]
+: 230.1652 
found 230.1649.  
 
General method for P-stereogenic phosphine coupling.  
A solution of tert-butylmethylphosphinous acid borane diisopropyl ammonium salt (1 eq) 
and methansulfonic anhydride 97% (1.2 eq) in CH2Cl2 (0.2 M) was cooled down to –20 
ºC. To this solution, anhydrous NEt3 (2.5 eq) was slowly added, and the mixture was 
stirred 1.5 h at –20 ºC. A solution of the corresponding amine (2 eq) in CH2Cl2 (0.2 M) 
was then added dropwise and the solution was stirred overnight at –20 ºC. Water was 
added to quench the reaction and the mixture was allowed to warm to room temperature. 
The organic layer was separated and the aqueous phase was extracted twice with CH2Cl2. 
The combined organic extracts were washed with NaOH (1M), HCl (1M) and water. 
Finally, the solution was dried over anhydrous MgSO4 and the volatiles were removed 
under vacuum.  
 
(S)-1-tert-butyl-1-methyl-N-((S)-2-methyl-1-(1-methyl-1H-benzo[d]imidazol-2-
yl)propyl)phosphanamine borane complex, (Ir-(SP)-8). 
Following the general procedure, benzoimidazole amine 4 (360 mg, 1.8 mmol), Ms2O 
(185 mg, 1.1 mmol), phosphinite salt (R)-1·DA (208 mg, 0.9 mmol) and NEt3 (0.3 ml, 
2.2 mmol) were employed. White solid; 273 mg (96%).  
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 [α]D: –18.3 (c 1.00, CHCl3). IR (KBr) ʋmax: 3317, 3032, 2963, 2378, 1467 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ 7.74 – 7.65 (m, 1H), 7.40 – 7.31 (m, 1H), 7.31 – 7.20 (m, 2H), 4.44 
(dt, J = 11 and 8 Hz, 1H), 3.83 (s, 3H), 2.79 (dd, J = 12 and 6Hz, 1H), 2.06 (h, J = 7 Hz, 
1H), 1.18 (d, JP = 14 Hz, 9H), 1.08 (d, J = 7 Hz, 3H), 1.02 (d, JP = 9 Hz, 3H), 0.91 (d, J 
= 7 Hz, 3H), 0.81 – -0.03 (m, 3H, BH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 157.4 (C), 
142.0 (C), 135.3 (C), 122.3 (CH), 122.1 (CH), 118.9 (CH), 109.6 (CH), 55.1 (CH), 35.7 
(d, JP = 8 Hz, CH), 30.6 (C), 30.1 (CH3), 24.4 (d, JP = 3 Hz, 3xCH3), 19.4 (CH3), 18.6 
(CH3), 10.4 (d, JP = 32 Hz, CH3) ppm. 
31P NMR (202 MHz, CDCl3) δ 71.5 (q, J = 51 Hz) 
ppm. HRMS (ESI): calc for [M+H]+: 318.2265, found 318.2265. 
 
(R)-1-tert-butyl-1-methyl-N-((S)-2-methyl-1-(1-methyl-1H-benzo[d]imidazol-2-
yl)propyl)phosphanamine borane complex, (Ir-(RP)-8).  
Following the general procedure, benzoimidazole amine 4 (403 mg, 2 mmol), Ms2O (213 
mg, 1.2 mmol), phosphinite salt (S)-1·DA (233 mg, 1 mmol) and NEt3 (0.3 ml, 2.5 mmol). 
Oil; 240 mg (76%). 
 [α]D: –42.9 (c 1.06, CHCl3). IR (KBr) ʋmax: 3345, 2963, 2870, 2377, 1467 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ 7.84 – 7.74 (m, 1H), 7.48 – 7.33 (m, 3H), 4.51 (q, J = 10 Hz, 1H), 
3.91 (s, 3H), 3.63 (d, J = 11 Hz, 1H), 2.33 (dp, J = 8 and 7 Hz, 1H), 1.39 (d, J = 9 Hz, 
3H), 1.30 (d, J = 7 Hz, 3H), 1.13 (d, J = 7 Hz, 3H), 0.89 (d, J = 14 Hz, 9H), 0.78 (d, J = 
7 Hz, 3H) 0.65 – 0.00 (m, 3H, BH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 157.2 (C), 137.5 
(C), 133.4 (C), 124.1 (CH), 123.9 (CH), 117.7 (CH), 110.3 (CH), 55.6 (d, JP = 4 Hz, CH), 
35.8 (d, JP = 8 Hz, CH), 31.1 (C), 30.7 (CH3), 24.3 (d, JP = 3 Hz, 3xCH3), 19.3 (CH3), 
19.2 (CH3), 11.4 (d, JP = 43 Hz, CH3) ppm. 
31P NMR (202 MHz, CDCl3) δ 74.4 (q, J = 
56 Hz) ppm. HRMS (ESI): calc for [M+H]+: 320.2421, found 320.2422.  
 
(S)-1-tert-butyl-1-methyl-N-((S)-2-methyl-1-(1-methyl-4-phenyl-1H-imidazol-2-
yl)propyl)phosphanamine borane complex, (Ir-(SP)-9).  
Following the general procedure; phenylimidazole amine 7 (402 mg, 1.8 mmol), Ms2O 
(186 mg, 1.1 mmol), phosphinite salt (R)-1·DA (205 mg, 0.9 mmol) and NEt3 (0.3 ml, 
2.2 mmol). White solid; 300 mg (99%).  
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Mp = 117 – 119 ºC. [α]D: –73.4 (c 1.09, CHCl3). IR (KBr) ʋmax: 2962, 2870, 2378, 1607 
cm-1. 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.65 (m, 2H), 7.40 – 7.32 (m, 2H), 7.24 – 7.19 
(m, 1H), 7.03 (s, 1H), 4.12 (dt, J = 11 and 8 Hz, 1H), 3.70 (s, 3H), 1.99 (h, J = 7 Hz, 1H), 
1.18 (d, JP = 14 Hz, 9H), 1.06 (d, J = 7 Hz, 3H), 1.03 (d, JP = 9 Hz, 3H), 0.88 (d, J = 7 
Hz, 3H), 0.80 – -0.05 (m, 3H, BH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 150.9 (C), 140.0 
(C), 128.5 (2xCH), 126.5 (CH), 124.8 (2xCH), 115.9 (CH), 54.9 (CH), 35.9 (d, JP = 9 
Hz, CH), 33.0 (CH3), 30.5 (C), 24.4 (d, JP = 2 Hz, CH3), 19.4 (CH3), 18.9 (CH3), 10.3 (d, 
JP = 31 Hz, CH3) ppm. 
31P NMR (202 MHz, CDCl3) δ 71.4 – 69.9 (m) ppm. HRMS (ESI): 
calc for [M+H]+: 346.2578, found 346.2584.  
 
(R)-1-tert-butyl-1-methyl-N-((S)-2-methyl-1-(1-methyl-4-phenyl-1H-imidazol-2-
yl)propyl)phosphanamine borane complex, (Ir-(RP)-9).  
Following the general procedure; phenylimidazole amine 7 (399 mg, 1.8 mmol), Ms2O 
(186 mg, 1.1 mmol), phosphinite salt (S)-1·DA (206 mg, 0.9 mmol) and NEt3 (0.3 ml, 2.2 
mmol). White solid; 172 mg (57%).  
Mp = 185 – 187 ºC. [α]D: –122.0 (c 1.02, CHCl3). IR (KBr) ʋmax: 3333, 2957, 2872, 2370, 
2347, 1463 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.68 (m, 2H), 7.39 – 7.32 (m, 2H), 
7.25 – 7.19 (m, 1H), 6.99 (s, 1H), 4.19 (td, J = 10 and 8 Hz, 1H), 3.68 (s, 3H), 2.79 (d, JP 
= 11 Hz, 1H, NH), 2.02 (m, 1H), 1.35 (d, JP = 9 Hz, 3H), 1.06 (d, J = 7 Hz, 3H), 0.90 (d, 
JP = 14 Hz, 9H), 0.82 (d, J = 7 Hz, 3H), 0.53 (m, 3H, BH3) ppm. 
13C NMR (101 MHz, 
CDCl3) δ 151.4 (C), 140.2 (C), 134.4 (C), 128.5 (2xCH), 126.6 (CH), 124.8 (2xCH), 
115.4 (CH), 55.0 (d, JP = 3 Hz, CH), 36.1 (d, JP = 6 Hz, CH), 33.0 (CH3), 30.5 (C), 24.3 
(d, JP = 3 Hz, CH3), 19.2 (CH3), 19.0 (CH3), 11.1 (d, JP = 45 Hz, CH3) ppm. 
31P NMR 
(202 MHz, CDCl3) δ 73.0 (q, J = 57 Hz) ppm. HRMS (ESI): calc for [M+H]
+: 346.2580, 
found 346.2582.  
 
General procedure for the synthesis of Ir-[P,N] catalysts.  
The corresponding borane protected ligand (1 eq) was dissolved in dry distilled 
pyrrolidine under nitrogen (0.06 M) and stirred overnight at 90 ºC. Pyrrolidine was then 
removed in high vacuum. The crude was further dried under vacuum for 30 min at 50 ºC. 
A solution of [Ir(COD)(Cl)]2 (0.5 eq) in CH2Cl2 (0.06 M) was added to the free ligand 
via cannula. The resulting mixture was stirred for 40 min at room temperature. NaBArF 
(1 eq) was then added and the solution was stirred 1 h at room temperature. The resulting 
16 
 
crude was filtered through a small plug of silica gel under N2 and washed with dry Et2O, 
eluting with hexanes/CH2Cl2 (50-100%). The orange coloured fraction was collected and 
concentrated to yield the corresponding Ir complexes as orange solids. 
 
[Ir(COD)(SP-8)][BArF].  
Following the general procedure; ligand (SP)-8 (45 mg, 0.14 mmol), pyrrolidine (2.5 ml), 
[Ir(COD)(Cl)]2 (47 mg, 0.07mmol), NaBArF (125 mg, 0.14 mmol) were employed. 
Orange solid; 180 mg (87 %).  
Mp = 187 – 188 ºC.  [α]D: +34.9 (c 1.02, CHCl3). IR (KBr) ʋmax: 3417, 2958, 2918, 2843, 
1606, 1454, 1351, 1270, 1124 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.75 (m, 1H), 
7.71 (m, 8H, BArF
–), 7.52 (s, 4H, BArF
–), 7.46 – 7.37 (m, 3H), 5.37 (p, J = 8 Hz, 1H, 
COD), 4.72 (d, J = 5 Hz, 1H, COD), 4.03 (d, J = 6 Hz, 1H, COD), 3.92 (ddd, J = 23, 11 
and 7 Hz, 1H), 3.80 (s, 3H), 3.61 (m, 1H), 3.48 – 3.41 (m, 1H, COD), 2.64 (m, 2H, COD), 
2.36 (d, JP = 15 Hz, 1H, COD), 2.30 (d, JP = 6 Hz, 1H, NH), 2.24 – 2.06 (m, 3H, COD), 
1.41 (d, JP = 8 Hz, 3H), 1.20 (d, J = 6 Hz, 3H), 0.83 (d, J = 7 Hz, 3H), 0.76 (d, JP = 15 
Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 161.7 (q, JB = 50 Hz, BArF, 4xC) 155.4 (C), 
138.8 (C), 136.0 (BArF, 8xCH), 134.0 (C), 129.2 (m, BArF, C), 128.9 (m, BArF, CF3), 
126.1 (CH), 125.2 (CH), 117.9 (BArF, 4xCH), 117.7 (CH), 115.7 (CH), 96.0 (COD, CH), 
91.4 (COD, CH), 61.5 (COD, CH), 61.1 (COD, CH), 59.2 (d, JP = 4 Hz, CH), 39.8 (d, JP 
= 4 Hz, CH), 37.2 (d, JP = 4 Hz, COD, CH2), 36.4 (d, JP = 37 Hz, C), 32.8 (d, JP = 2 Hz, 
COD, CH2), 31.0 (CH3), 28.7 (COD, CH2), 25.8 (3xCH3), 25.7 (COD, CH2) 20.0 (CH3), 
18.6 (CH3), 8.8 (d, JP = 35 Hz, CH3) ppm. 
31P NMR (202 MHz, CDCl3) δ 56.2 (s) ppm. 
HRMS (ESI): calc for [M+H]+: 606.2584, found 606.2588; calc for [M–H]–: 863.0643, 
found 863.0636.  
 
[Ir(COD)(RP-8)][BArF] 
Following the general procedure; ligand (RP)-8 (50 mg, 0.16 mmol), pyrrolidine (2.5 ml), 
[Ir(COD)(Cl)]2 (53 mg, 0.07mmol), NaBArF (139 mg, 0.14 mmol) were employed. 
Orange solid; 80 mg (35 %). 
Mp =152 – 155 ºC.  [α]D: +66.0 (c 1.01, CHCl3). IR (KBr) ʋmax: 3417, 2950, 2914, 2851, 
1601, 1484, 1353, 1271, 1116 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.85 (m, 1H), 
7.70 (p, J = 2 Hz, 8H, BArF
–), 7.51 (s, 4H, BArF
–), 7.48 – 7.42 (m, 2H), 7.42 – 7.36 (m, 
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1H), 4.98 (s, 1H, COD), 4.80 (s, 2H, COD), 4.01 (d, J = 7 Hz, 1H, COD), 3.90 – 3.77 (m, 
1H, COD), 3.74 (s, 3H), 3.30 (br. s, 1H, COD), 2.59 (br. s, 1H, COD), 2.45 (br. s, 1H, 
COD), 2.19 (br. s, 4H), 2.08 (br. s, 1H, NH), 1.55 (br. s, 2H), 1.31 (d, JP = 6 Hz, 3H), 
1.13 (d, JP = 16 Hz, 9H), 0.91 (d, J = 7 Hz, 3H), 0.78 (d, J = 7 Hz, 3H) ppm. 
13C NMR 
(101 MHz, CDCl3) δ 161.6 (q, JB = 50 Hz, BArF, 4xC), 138.4 (C), 135.9 (BArF, 8xCH), 
(m, BArF, C), 128.9 (m, BArF, CF3), 126.0 (CH), 125.2 (CH), 118.5 (BArF, 4xCH), 117.6 
(CH), 111.8 (CH), 110.2 (C), 94.3 (COD, CH), 85.6 (COD, CH), 65.7 (COD, CH), 58.0 
(CH), 56.6 (COD, CH), 38.0 (CH), 37.5 (COD, 2xCH2), 34.8 (C), 33.5 (COD, CH2), 31.0 
(CH3), 29.5 (COD, CH2), 25.8 (3xCH3), 25.3 (COD, CH2) 20.8 (CH3), 19.0 (CH3), 14.2 
(CH3) ppm. 
31P NMR (202 MHz, CDCl3) δ 60.6 (s), ppm. HRMS (ESI): calc for [M+H]
+: 
606.2584, found 606.2580; calc for [M–H]–: 863.0643, found 863.0672.  
 
[Ir(COD)(SP-9)][BArF].  
Following the general procedure; ligand (SP)-9 (50 mg, 0.15 mmol), pyrrolidine (2.5 ml), 
[Ir(COD)(Cl)]2 (45 mg, 0.07mmol), NaBArF (128 mg, 0.14 mmol) were employed. 
Orange solid; 173 mg (82 %).  
Mp = 201 – 203 ºC.  [α]D: +46.6 (c 1.02, CHCl3). IR (KBr) ʋmax: 3417, 2954, 2923, 2851, 
1614, 1459, 1353, 1271, 1127 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 2H), 7.73 – 
7.69 (m, 8H), 7.53 (s, 4H), 7.48 – 7.43 (m, 3H), 7.00 (s, 1H), 4.62 (br. s, 1H, COD), 4.17 
(m, 1H, COD), 3.75 (ddd, JP = 23, J = 11 and 7 Hz, 1H), 3.64 (s, 3H), 3.59 (m, 1H+1H 
COD), 3.34 (m, 1H, COD), 2.45 (m, 2H, COD), 2.27 – 2.17 (m, 2H, COD), 2.13 – 1.99 
(m, 2H, COD), 1.46 (m, 2H, COD), 1.42 (d, JP = 8 Hz, 3H), 1.16 (d, J = 6 Hz, 3H), 0.92 
(d, JP = 15 Hz, 9H), 0.77 (d, J = 7 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3) δ 161.8 (q, 
JB = 50 Hz, BArF, 4xC), 149.8 (C), 140.9 (C), 134.9 (BArF, 8xCH), 129.7 (2xCH), 129.2 
(m, BArF, C), 128.9 (CH), 128.9 (m, BArF, CF3), 127.9 (2xCH), 120.6 (C), 120.1 (CH), 
117.6  (d, J = 4 Hz, BArF, 4xCH) 110.2 (C), 96.3 (d, J = 11 Hz, COD, CH), 92.1 (d, J = 
13 Hz, COD, CH), 61.7 (COD, CH), 61.3 (COD, CH), 58.8 (d, J = 4 Hz, CH), 39.5 (CH), 
37.4 (d, J = 4 Hz, COD, CH2), 34.4 (CH3), 33.3 (COD, CH2), 29.9 (C), 28.3 (COD, CH2), 
25.4 (d, J = 5 Hz, 3x CH3), 20.0 (CH3), 18.6 (CH3), 9.7 (d, J = 35 Hz, CH3) ppm. 
31P 
NMR (202 MHz, CDCl3) δ 54.7 (s) ppm. HRMS (ESI): calc for [M+H]
+: 632.2740, found 





Following the general procedure; ligand (RP)-9 (50 mg, 0.15 mmol), pyrrolidine (2.5 ml), 
[Ir(COD)(Cl)]2 (45 mg, 0.07mmol), NaBArF (128 mg, 0.14 mmol) were employed. 
Orange solid; 118 mg (54 %).  
Mp = 173 – 175 ºC. [α]D: +52.8 (c 1.03, CHCl3). IR (KBr) ʋmax: 3412, 2959, 2918, 2843, 
1606, 1476, 1353, 1274, 1119 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.93 – 7.87 (m, 2H), 
7.73 – 7.67 (m, 10H), 7.52 (s, 4H), 7.50 – 7.44 (m, 3H), 7.01 (s, 1H), 5.02 (d, J = 8 Hz, 
1H, COD), 4.63 (d, J = 6 Hz, 1H, COD), 3.90 (d, J = 8 Hz, 1H, COD), 3.73 – 3.60 (m, 
1H), 3.59 (s, 3H), 3.42 (p, J = 8 Hz, 1H), 3.32 (m, 1H, COD), 2.43 – 2.30 (m, 1H), 2.18 
(dd, J = 15 and 8 Hz, 1H), 2.13 – 2.00 (m, 4H), 1.54 (s, 2H), 1.27 (d, JP = 6 Hz, 3H), 1.25 
(d, J = 8 Hz, 3H), 1.16 (d, J = 15 Hz, 9H), 0.76 (d, J = 7 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 161.7 (q, JB = 50 Hz, BArF, 4xC), 150.0 (C), 141.3 (C), 134.9 (BArF, 
8xCH), 129.2 (2xCH), 129.2 (m, BArF, C), 128.9 (m, BArF, CF3), 126.0 (C), 127.3 
(2xCH), 123.3 (C), 120.2 (CH), 117.6 (BArF, 4xCH), 94.1 (d, J = 10 Hz, COD, CH), 87.7 
(d, J = 15 Hz, CH), 65.1 (COD, CH), 56.0 (COD, CH), 37.6 (CH), 37.3 (COD, CH2), 37.3 
(COD, CH2), 34.5 (CH3), 33.6 (COD, CH2), 29.9 (COD, CH2), 20.0 (COD, CH2), 26.0 
(d, J = 4 Hz, 3x CH3), 20.9 (CH3), 19.0 (CH3), 15.7 (CH3) ppm. 
31P NMR (202 MHz, 
CDCl3) δ 58.2 (s) ppm. HRMS (ESI): Calc for [M+H]
+: 632.2740, found 632.2750; calc 
for [M–H]–: 863.0643, found 863.0687. 
 
Hydrogenation reactions.  
N-acetyl-3,4-dihydronaphthalen-2-amine (1 eq) and the corresponding catalyst (0.01 eq) 
were weighted in a test tube and then placed in a stainless steel high pressure reactor. The 
corresponding solvent was added and the reactor was closed and connected to a hydrogen 
manifold. While stirring, the reactor was purged with vacuum-nitrogen cycles and then 
vacuum-hydrogen cycles. Finally it was charged at the corresponding hydrogen pressure. 
The hydrogen manifold was unplugged and the mixture was left to stir overnight at room 
temperature. The reactor was depressurized. The mixture crude was dried, and at this 
point the conversion was determined by 1H NMR analysis. Determination of the optical 
purity was carried out by chiral HPLC upon solving the sample in heptane/isopropyl 
alcohol (1:1) and filtration.  
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1H NMR (400 MHz, CHCl3) δ 7.19 – 7.01 (m, 3H), 4.37 – 4.24 (m, 1H), 3.18 – 3.08 (m, 
1H), 2.98 – 2.79 (m, 2H), 2.69 – 2.59 (m, 1H), 2.05 (m, 1H), 1.98 (s, 3H), 1.79 (m, 1H) 
ppm. HPLC: CHIRALCEL OJ. Heptane/i-PrOH 70:30-0.2% NEt3, 0.5 mL/min, λ = 254 
nm. t(S) (–)= 8.1 min, t(R) (+)= 9.4 min.  
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